Solstice Advanced Materials Inc. filed a Form 8-K on August 27, 2026, disclosing the mutual termination of its Agreement and Plan of Merger with Element Solutions Inc. and announcing a new $500 million share repurchase program.
Lam Research Corporation filed an 8-K with the U.S. Securities and Exchange Commission on August 27, 2026, disclosing that two members of its Board of Directors notified the company of their decisions to retire effective November 2, 2026.
George Kurtz, President and CEO of CrowdStrike Holdings, Inc. (NASDAQ:CRWD), filed a Form 4 on August 27, 2026, disclosing the sale of Class A common stock across multiple transactions on August 25 and August 26, 2026, pursuant to a Rule 10b5-1 plan.
Roivant Sciences Ltd. filed a Form 8-K on August 27, 2026, disclosing that the U.S. Food and Drug Administration approved the New Drug Application for LISRAYA (brepocitinib) for the treatment of adults with dermatomyositis.
A Form 4 filed on August 27, 2026, discloses that Adrian T. Dillon, a director of HealthEquity, Inc. (NASDAQ:HQY), exercised stock options and sold shares of common stock on August 25, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
Standard Nuclear, Inc. (NYSE:STDN) filed its Form 10-Q for the quarterly period ended June 30, 2026, disclosing share counts, IPO details, facility status, and key business arrangements.
IREN Limited filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission on August 27, 2026, covering the fiscal year ended June 30, 2026.
Workday, Inc. filed its Form 10-Q for the quarterly period ended July 31, 2026, with the Securities and Exchange Commission, disclosing unaudited financial results for the three and six months ended July 31, 2026.
Therapeutic cancer vaccines were, until recently, a loosely bunched field of similarly staged developers running comparable trials on a shared mRNA premise. That is no longer an accurate description. One well-funded developer has been through bankruptcy court. Another has been fully absorbed into a …
Alphabet Inc (NASDAQ:GOOGL) raised its 2026Capital Expenditureguidance alongside second-quarterEarningsin late July, and the market response was immediate. Shares slid even though cloud revenue growth had accelerated sharply from the prior year, and the company's quarterly free cash flow turned negative for the first time …